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Circulating CD56bright NK cells 
inversely correlate with survival of 
melanoma patients
Kaat de Jonge  1, Anna ebering1, sina Nassiri1,3, Hélène Maby-el Hajjami  1, 
Hajer ouertatani-sakouhi1, petra Baumgaertner1 & Daniel e. speiser1,2
the roles of NK cells in human melanoma remain only partially understood. We characterized NK cells 
from peripheral blood ex vivo by flow cytometry obtained from late stage (III/IV) melanoma patients. 
Interestingly, we found that the abundance of CD56bright NK cells negatively correlate with overall 
patient survival, together with distant metastases, in a multivariate cox regression analysis. the 
patients’ CD56bright NK cells showed upregulation of CD11a, CD38 and CD95 as compared to healthy 
controls, pointing to an activated phenotype as well as a possible immune regulatory role in melanoma 
patients. After stimulation in vitro, CD56bright NK cells produced less tNFα and GMCsF in patients than 
controls. Furthermore, IFNγ production by the CD56bright NK cells correlated inversely with overall 
survival. Our results highlight that abundance and function of CD56bright NK cells are associated with 
melanoma patient survival, emphasizing the potential of NK cell subsets for biomarker discovery and 
future therapeutic targeting.
Melanoma is, next to squamous cell carcinoma and basal cell carcinoma, one of the three major types of skin 
cancer1. Due to its highly metastatic potential, with metastases developing amongst others in lymph nodes, liver, 
lung and brain, the mortality rate is highest for melanoma amongst the three skin cancer types, although being 
the least frequent. While the number of people suffering from melanoma grows worldwide, the survival rates 
of metastatic melanoma patients remain inadequate. Treatments with immune checkpoint blocking antibodies 
such as Ipilimumab (anti-CTLA-4) and Nivolumab (anti-PD1) result in progressively increased rates of clini-
cal responses. However, many patients still do not respond to available therapies2. Mechanisms of response to 
checkpoint blockade are not completely understood. Among other players, NK cells may potentially modulate 
immunotherapy effects3.
NK cells are part of the innate immunity branch of the group of innate lymphoid cells (ILC)4. They are 
potent killers of virally infected as well as cancer cells without needing prior sensitizations5. Moreover, they are 
potent cytokine producers6. In humans, NK cells can be divided into two main subsets, comprising the imma-
ture, poorly cytotoxic but cytokine-producing CD56bright, and the mature, cytolytic, weakly cytokine-producing 
CD56dimCD16+ NK cells. CD56bright NK cells only make up around 10% of NK cells in the periphery; they are, 
however, the major subtype in tissues and second lymphoid organs7.
NK cells are often seen as a positive factor in the anti-tumour immune response since their involvement in 
immune surveillance has been shown multiple times8–11. For example, in rag mice that lack an adaptive immune 
system, the production of IFNγ by NK cells was found indispensable in the immune editing process12. Additionally, 
mice without natural killer cells are less able to reject several tumour cell lines, including B16 melanoma cells8. 
Moreover, injection of pre-activated murine NK cells persisted within the tumour and they were able, in combi-
nation with radiotherapy, to significantly reduce the growth of primary tumours and metastases13. In melanoma 
patients, NK cells have been studied in both the peripheral blood as well as in tissues, however they are yet insuf-
ficiently characterized and contradictory results have been found14. Some investigators have reported unaltered 
frequencies of CD56bright and CD56dim subsets in blood of metastatic melanoma patients15,16, whereas others have 
found a decrease in both subsets17. Moreover, peripheral NK cells appeared to have impaired IFNγ production and 
degranulation15,18. CD56dim NK cells derived from blood expressed lower levels of the activation receptor NKG2D, 
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and CD56bright NK cells expressed higher levels of the inhibitory KIR receptor CD158b15. Fregni et al. reported 
decreased expression of the natural cytotoxicity receptor NKp46, in line with previous publications. However, they 
reported no significant differences between patient and healthy controls in the production of IFNγ and the degran-
ulation marker CD107a16. NK cells are able to infiltrate primary tumours especially in the peritumoral area16. Tirosh 
et al. characterized the tumour micro-environment (TME) in metastatic melanoma by single cell analysis and found 
NK cells present in small numbers within the tumor19. The presence of total NK cells in the TME was found to pos-
itively correlate with clinical outcome in patients with colorectal carcinoma, gastric carcinoma and non-squamous 
lung carcinoma20–22. Little information is available about NK cell phenotype and functionality in primary mela-
noma. One study showed that NK cells within tumour-infiltrating lymphocytes (TILs) are CD56brightCD16dim, a 
phenotype that is also found in regulatory decidual NK cells14. Other studies have focused on the NK cell pheno-
type in tumour-infiltrated lymph nodes, reporting an enrichment of CD57+KIR+CD56dim NK cells, which are very 
efficient at killing autologous melanoma cell lines17, suggesting a fully mature and effector phenotype. The ratio of 
CD56dimCD57+ to CD56brightCD57+ seems to be biologically important and associated with survival in stage III mel-
anoma patients17. Messaoudene et al. reported the presence of activated NK cells in tumour-infiltrated lymph nodes, 
expressing higher levels of NKp46, NKG2D, NKp44, DNAM-1 and NKp30. Moreover, they found a population of 
CD56bright NK cells expressing CD16 as well as other activation receptors and KIRs. This population could also be 
found in lymph nodes adjacent to tumour-infiltrated lymph nodes but not in the blood23.
NK cell based therapies have not been successful in solid tumors24. However, NK cells are associated with 
durable responses after various therapies. NK cells are mediators of antibody-dependent cell cytotoxicity and have 
been shown to interact with α-CTLA-4 antibody, whilst at the same time inducing NK cell maturation25. A new 
experimental therapy targeting both CD8 T cells and NK cells by blocking the NKG2A receptor has shown early 
promising results in squamous cell carcinoma patients26. Interestingly, the frequency at baseline of CD56bright NK 
cells in blood of melanoma patients treated with Ipilimumab was negatively correlated with overall survival27.
Our goal was to characterize circulating NK cells and their subpopulations as well as their functionality in late stage 
(III/IV) melanoma patients. We hypothesized that apart from a reduced anti-tumour function they could also play reg-
ulatory roles. We found that CD56bright NK cells are negatively correlated with overall survival of the melanoma patients. 
Therefore, we determined the phenotypic and functional characteristics of circulating CD56bright NK cells, improving 
the basis for a better understanding of NK cell tumour biology and future optimization of cancer immunotherapy.
Results
The frequency of circulating CD56bright NK cells correlates inversely with patient survival. We 
studied 29 late stage (III/IV) melanoma patients28 included in a vaccine clinical trial, and focused on NK cells 
before treatment start. PBMCs were analysed directly ex vivo by flow cytometry, using the gating strategy as 
represented in Figure 1A. 1 patient was excluded due to technical issues. 13 healthy donors were included as 
controls. We found no difference in the frequency of total NK cells as well as CD56bright, CD56dimCD16+ and 
CD56dimCD16− NK cells between patients and healthy donors (Fig. 1B). Interestingly, patients with high frequen-
cies or absolute numbers of CD56bright NK cells had significantly shorter overall survival than patients with low 
frequencies or absolute numbers (Fig. 1C,D). We did not find a significant correlation between absolute numbers 
of CD56bright and CD56dimCD16+ NK cells, indicating that the negative correlation between overall survival and 
the number of CD56bright NK cells is not a result of corresponding low numbers of CD56dimCD16+ NK cells 
(Fig. 1D). Frequencies and numbers of peripheral CD56bright NK cells did not only inversely correlate with overall 
but also progression free survival (Fig. 1E). No significant correlation was observed between patient survival and 
total NK cells, or CD56dimCD16+ or CD56dimCD16− NK cells (Fig. 1C). Frequencies of NK cells and their subsets 
were similar in healthy donors and melanoma patients at stage III and IV (Suppl. Fig. 1A). Numbers of CD56bright 
NK cells does not significantly differ between stage III and IV patients (Suppl. Fig. 1B). Frequencies of CD56bright 
NK cells are not significantly different between patients having received any previous treatment (chemo, radio 
or immunotherapy) (Suppl. Fig. 1C–E). Since CD56bright NK cells seem to be a prognostic factor for survival, we 
decided to characterize them in more detail.
CD56bright NK cells have an activated phenotype in patients. Patient and healthy control NK cells 
were analysed for the expression levels of multiple NK cells markers, inhibitory and activating receptors as well 
as activation markers by flow cytometry. As compared to healthy donors, circulating CD56bright NK cells of mela-
noma patients showed elevated expression of CD11a, CD38 and CD95, as measured directly ex vivo (Fig. 2A,B). 
The observations were consistent after patients were stratified according to their disease status: stage III or IV 
(Fig. 2C). We did not observe any difference in the expression levels of NKG2A, NKp46 or NKG2D (Fig. 2D), 
and these markers were also consistently expressed in patients at different disease stages (Fig. 2E). We did not 
observe expression of KLRG1, CD158b1,b2,j (a pan KIR marker) or CD57 (data not shown). Elevated expression 
of CD11a, CD38 and CD95 indicates an activated phenotype. Moreover, CD38 is part of the adenosine pathway29; 
adenosine is a immunoregulatory factor that promotes regulatory T cells and inhibits conventional T cell func-
tion30. We found a trend for increased CD38 expression on CD56bright NK cells and the prevalence of regulatory 
T cells (Fig. 2F). Despite the elevated expression of CD95 (FasR) we did not see evidence for increased apoptosis 
of the CD56bright NK cells as measured by Annexin V (Suppl. Fig. 2A). CD56dimCD16+ NK cells also seem to have 
an activated phenotype as characterized by higher expression of CD11a, CD95 and NKG2D. They are less highly 
differentiated than their counterpart in healthy donors as characterized by a lower frequency of CD57 expressing 
cells (Suppl. Fig. 2B,C). Levels of NKp46, NKG2A, KLRG1, CD38, CD95 and CD158b1,b2,j on CD56dimCD16+ 
NK cells were not found to be different between patients and healthy donors (Suppl. Fig. 2B). Finally, we found no 
expression of PD-1 and CTLA-4 by either CD56bright or CD56dimCD16+ NK cells (data not shown).
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Figure 1. Frequencies of NK cells in melanoma patients and healthy controls. (A) Representative dot plots of 
the gating strategy used. Lymphocytes were selected using forward (FSC) and side scatter (SSC), afterwards 
doublets were gated out and live cells were selected. A series of negative selections was performed, first gating 
out DCs, monocytes and B cells using a lineage cocktail, next T cells and ILCs were gated out using CD3 and 
CD127. Total NK cells were positively selected using CD56 (total NK cells), this population can be further 
divided into CD56bright, CD56dimCD16+ and CD56dimCD16− NK cells. (B) Histograms of the frequencies of total 
NK cells, CD56bright, CD56dimCD16+ and CD56dimCD16− NK cells, as measured by flow cytometry in PBMC 
samples of 28 melanoma patients and 13 healthy donors. Frequencies of the patients with values lower than the 
median are indicated in red, and those higher than the median are indicated in grey. (C) Kaplan-Meier curves 
of overall survival, of patients with high (grey) vs. low (red) percentages of total NK cells, CD56dimCD16 + , 
CD56dimCD16− and CD56bright NK cells, with the median as cut-off. (D) Absolute numbers of corresponding 
CD56dimCD16+ and CD56bright NK cells represented in a xy-plot. Kaplan-Meier curves of overall survival with 
high (grey) vs. low (red) numbers of CD56bright NK cells, with the median as cut-off. E. Kaplan-Meier curves 
of progression free survival with high (grey) and low (red) frequencies and absolute numbers of CD56bright NK 
cells with the median as cut-off. ns not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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Pro-inflammatory cytokine and chemokine production is partially affected in CD56bright NK 
cells. Since CD56bright NK cells have an activated phenotype we wondered if they are also more capable of pro-
ducing cytokines and chemokines than NK cells from healthy donors. Previous publications have shown that NK 
cells are able to produce an array of cytokines, including Th1, Th2 as well as regulatory cytokines31. We used sam-
ples from 12 patients representing the whole patient population based on their frequencies of CD56bright NK cells 
(Fig. 3A), and the same previously used 13 healthy donors as controls. We stimulated NK cells for 4 hours with PMA/
Ionomycin and analysed them by flow cytometry. ILCs were excluded by gating out CD127-positive cells. Previous 
Figure 2. Phenotypic characterization of CD56bright NK cells by flow cytometry. (A) Representative histograms 
of the expression level (Median Fluorescent Intensity, MFI) of CD11a, CD38 and CD95 on CD56bright NK cells. 
The histograms show overlays; patient LAU975 (grey) and healthy donor 7 (black). (B) Summary histograms 
of the expression levels (MFI) of CD11a, CD38 and CD95. (C) Distribution of the expression levels (MFI) of 
CD11a, CD38 and CD95 from patients with late stage (III/IV) melanoma and healthy donors. (D) Summary 
histograms of the expression levels (MFI) of NKp46, NKG2D and NKG2A. (E) Distribution of the expression 
levels (MFI) of NKp46, NKG2D and NKG2A from patients with late stage (IIII/V) melanoma and healthy 
donors. (F) Frequencies of regulatory T cells (CD25hiFoxP3+CD127−) in the blood of melanoma patients before 
vaccination (n = 21) correlating with the expression levels of CD38 (MFI) on CD56bright NK cells (n = 21) from 
the same patients. ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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studies have reported decreased functionality of peripheral blood NK cells in melanoma patients15. We did not 
detect any differences between the amounts of IFNγ or CCL4 produced by CD56bright NK cells from patients and 
healthy donors (Fig. 3B,C). In contrast, we found lower production of TNFα and GMCSF (and a trend for CCL3) in 
patients as compared to healthy donors (Fig. 3B,D). We did not find differences for granzyme B and perforin expres-
sion before stimulation, suggesting similar cytolytic capacity (Fig. 3B,E). IFNγ, GMCSF, perforin, granzyme B, CCL4 
and NKp44 production by CD56dimCD16+ cells did not differ between patients and healthy donors. In turn, the 
patients produced lower levels of TNFα and CCL3 (Suppl. Fig. 3A,B). Finally, we did not observe any production of 
IL-10, IL-2, LTα, IL-4, IL-13, IL-22 and IL-5 in either subset (CD56bright and CD56dimCD16+) (data not shown). Even 
though CD56bright NK cells display an activated phenotype based on surface markers, they are not more functional 
than healthy controls, they are even impaired in the production of a number of cytokines.
Multivariate analysis shows significant correlation of CD56bright NK cells with overall patient sur-
vival. We used the clinical as well as phenotypical and functional data from our cohort to perform a univariate 
Cox regression analysis for overall patient survival, with the aim to identify significant clinical and immunological 
Figure 3. Functional characterization of CD56bright NK cells after stimulation (4 hours) with PMA/Ionomycin. 
(A) Histogram of the frequencies of CD56bright NK cells in patients and healthy donors. Patients included 
in subsequent functional experiments are indicated in red. (B) Representative dot plots of CCL4, IFNγ, 
GMCSF, CCL3 and TNFα after 4 hours of PMA/Ionomycin stimulation, and of perforin and granzyme B 
without stimulation of patient LAU627. (C) Histograms of IFNγ and CCL4 production (%) (CD56bright NK 
cells) in healthy donors and patients before and after stimulation. (D) Histograms of TNFα, GMCSF and 
CCL3 production (%) (CD56bright NK cells) in healthy donors and patients before and after stimulation. (E) 
Histograms of granzyme B and perforin (%) (CD56bright NK cells) in healthy donors and patients before 
stimulation. ns not significant *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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factors. One of the immunological parameters is the frequency of Melan-A specific CD8+ T cells at baseline, as previ-
ously described28. Interestingly, we found that presence of distant metastases, frequency of circulating CD56bright NK 
cells, and production of IFNγ by CD56bright NK cells are inversely associated with overall patient survival (Table 1). 
To test if these three parameters contribute individually to survival we performed a multivariate Cox regression anal-
ysis. Since we only had 11 paired samples for our functional analyses, we decided to not analyse the impact of IFNγ 
production by CD56bright NK cells any further. Our multivariate analysis showed that both, the presence of distant 
metastases and the frequency of CD56bright NK cells correlated significantly with survival (Table 1). A similar result 
was obtained using absolute numbers of CD56bright NK cells instead of frequencies (data not shown). The frequency 
of CD56bright NK cells was similar in patients with or without distant metastases (Suppl. Fig. 4). Together, our data 
suggest that the fraction of circulating CD56bright NK cells may hold prognostic value in melanoma patients.
Discussion
New therapies focussing on blocking inhibitory receptors not only of CD8 T cells but also of NK cells have shown 
clinical success26, supporting the notion that NK cells could have potentially important roles in future treatments. 
However, their implications in solid cancers is not entirely clear32. We analysed NK cells from a cohort of 29 
late stage (III/IV) melanoma patients included in a vaccine clinical trial. All analysis was performed on sam-
ples from before vaccine treatment. In patients and healthy donors we found similar frequencies of circulating 
total NK cells as well as their subsets (CD56dimCD16+ and CD56bright), in line with previously published data15,16. 
CD56dimCD16− NK cells were found reduced in viremic HIV patients33. We did not find significant differences 
between the frequencies of CD56dimCD16− NK cells in healthy controls and melanoma patients. In the literature, 
NK cells are frequently associated with immune surveillance, often playing significant roles in tumour control34. 
Interestingly, we found that higher frequencies and numbers of circulating CD56bright NK cells were associated 
with reduced overall and progression free patient survival, whereas frequencies or numbers of either total NK 
cells as well as CD56dim(CD16+ or CD16−) cells did not correlate with survival. A similar finding was previously 
reported by Tietze et al. who showed that low CD56bright NK cell frequency at baseline is a good predictor of mel-
anoma patient survival after treatment with Ipilimumab27.
Univariate Cox analysis Multivariate Cox analysis
beta HR
95% CI for 
HR P value beta HR 95% CI for HR P value
Age (years) −0.012 0.99 0.96–1 0.42
LDH (mgEq/l) −0.0025 1 0.99–1 0.59
Sex −0.17 0.84 0.33–2.2 0.73
Lymph node metastases −0.23 0.8 0.28–2.3 0.67
Satellite metastases 0.84 2.3 0.9–6 0.082
Distant metastases 1.1 3.1 0.97–6.5 0.031* 1.077 2.937 1.028–8.393 0.044*
N stage 0.83 2.3 0.66–7.9 0.19
DTH −0.95 0.39 0.13–1.1 0.082
NED or ED at study entry 0.92 2.5 0.97–6.5 0.059
Previous radiotherapy 0.096 1.1 0.32–3.8 0.88
Previous chemotherapy −0.26 0.77 0.22–2.7 0.68
Previous immunotherapy 0.076 1.1 0.42–2.8 0.88
Any previous therapy (Radio/Chemo/Immuno) −0.016 0.98 0.39–2.5 0.97
MelanA+ CD8 (% CD8+ T cells) −0.61 0.54 0.12–2.6 0.44
CD56Bright NK cells (% live lymphocytes) 2.9 18 2.4–140 0.005** 2.963 19.364 2.293–153–524 0.007**
CD11a (MFI) 1.3 3.7 0.049–280 0.56
NKp46 (MFI) 4.7 110 0.08–160 000 0.2
NKG2D (MFI) 1.9 6.4 0.19–220 0.3
NKG2A (MFI) 2.7 14 0.07–2900 0.33
CD38 (MFI) 0.42 1.5 0.015–160 0.86
CD95 (MFI) 0.96 2.6 0.027–260 0.68
CD16 (% CD56bright NK cells) 2.5 12 0.43–350 0.14
Granzyme B (% CD56bright NK) 4.7 110 0.54–20 000 0.083
Perforin (% CD56bright NK) 1.7 5.4 0.15–200 0.36
CCL4 (% CD56bright NK) −2 0.13 0.012–1.5 0.098
GMCSF (% CD56bright NK) −2 0.14 0.013–1.5 0.1
IFNγ (% CD56bright NK) 4.3 72 1.1–4700 0.044*
CCL3 (% CD56bright NK) 0.71 2 0.038–11 0.41
TNFα (% CD56bright NK) 1.9 6.9 0.35–140 0.21
Table 1. Univariate and multivariate analysis of overall survival by the Cox proportional hazards method. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Since CD56bright NK cells adversely correlated with overall survival, we wondered if they possessed regulatory 
characteristics or if they had any deficiencies in their anti-tumoural potential. Previous studies in melanoma 
patients have shown decreased expression of NKp46 and NKG2D as well as an increased expression of NKp44 in 
total NK cells15,16. We did not observe differences in expression of NKp46 and NKG2D on CD56bright NK cells. We 
found that CD56bright NK cells expressed higher levels of CD38, CD11a and CD95, indicating that these cells were 
activated. We did not, however find evidence for increased apoptosis. CD38 is an ADP ribosyl-cyclase, which has 
been described to be involved in the production of adenosine, limiting CD4+ T cell proliferation as well as induc-
ing regulatory T cells, mediated by CD56bright cells35. Indeed, we found that CD38 expression levels on CD56bright 
NK cells correlated with the frequencies of peripheral regulatory T cells from the same patients. Furthermore, 
CD11a was more strongly expressed on circulating CD56bright NK cells in patients than healthy donors. It is one of 
the receptors (together with NKp46 and NKG2D) that could induce NK cell cytotoxicity directed towards antigen 
specific, activated T cells; especially CD4+ T cells seem to be sensitive to NK cell lysis in a mouse model of LCMV 
infection36. NK cell regulation of T cell function was shown during the priming phase7, and NK cell depletion 
during a persistent LCMV infection also led to a positive therapeutic effect37. Perforin was found to be the most 
important mediator of T cell and NK cell mediated killing38.
Apart from expression of surface markers, we also determined the functionality of healthy donor and 
patient-derived NK cells. We analysed the production of an array of cytokines and chemokines while making 
sure that ILCs did not interfere with our analysis. Previously, ILCs have not been gated out when determining 
cytokine production15,16,31. We found no differences in the amounts of CCL4 and IFNγ produced by circulating 
CD56bright NK cells between patients and healthy donors. Unaffected production of IFNγ has been previously 
reported39. We found decreased production of TNFα and GMCSF by CD56bright NK cells. Even though CD56bright 
NK cells have a more activated phenotype in patients than healthy donors, they do not produce more cytokines. 
They are even partially impaired. GMCSF and TNFα are both pro-inflammatory cytokines. GMCSF can act in 
a paracrine manner and recruit neutrophils, monocytes and lymphocytes as well as enhance their functions. It 
plays an important role in priming of T cells as well as the development of a Th1 response40. In a phase II clinical 
trial, the administration of GMCSF to late stage melanoma patients in combination with Ipilimumab proved to 
be more efficient than Ipilimumab alone41. TNFα is known for its direct effects on cancer cells and for shaping the 
immune response42. It is also an essential cytokine for the process of antigen cross-presentation by DCs to CD8+ 
T cells43. In a mouse melanoma model, mice deficient for MIP-1α/β had increased tumour growth as well as a 
higher incidence of metastases, also associated with lower local production of IFNγ, TNFα and IL-644.
Univariate Cox regression analysis of multiple clinical and immunological parameters identified three signifi-
cant factors, namely the presence of distant metastases, the frequency of CD56bright NK cells and IFNγ production 
by CD56bright NK cells. IFNγ is usually seen as a positive mediator of the anti-tumour immune response. However, 
it has been shown that IFNγ produced by decidual NK cells has multiple immunoregulatory functions including 
inhibition of Th17 cells45, as well as induction of angiogenesis and vessel remodeling46. The interaction between 
decidual NK cells and monocytes leads to the induction of regulatory T cells as well as apoptosis of effector T 
cells, dependent of the IFNγ pathway47. The fact that distant metastases correlate with poor patient survival was 
expected as this is well known; patients without vs. with distant metastases are in stage III vs. IV, respectively; 
they have significantly different survival48,49. We did not observe a difference in CD56bright NK cell frequencies 
depending on the presence of distant metastases. Both are thus independent prognostic factors for overall sur-
vival of melanoma patients.
In primary tumours, NK cells are only present in low numbers, preferentially in the peritumoral area16. In 
lymph node metastases, NK cells can be found at similar frequencies as in healthy donor tissue, making up less 
than 5% of CD45+ cells23. Few specific markers exist to distinguish NK cell subsets in the TME16. As a result, it 
is challenging to detect NK cell subsets in histologic material or based on computational approaches using tran-
scriptome data50. Moreover, NK cells display a certain degree of plasticity51. Therefore our study was focused on 
circulating NK cells, specifically on CD56bright and CD56dim NK cells, their phenotype and functionality. Improved 
detection methods and studies are required to determine their roles and functions in the TME.
Our data suggest that CD56bright NK cells may have a negative effect on the anti-tumour response by inhibiting 
T cell responses, via CD38, perforin, CD11a and IFNγ. On the other hand they produce less GMCSF and TNFα, 
cytokines important in establishing an anti-tumour response. However, due to the limited amount of patients 
included in this study, these should be considered as preliminary findings and be confirmed in larger patient 
cohorts, including early disease patients. The effects on the anti-tumour immune response of CD56bright NK cells 
warrant also further mechanistic research. Our study provides evidence that the frequencies and absolute num-
bers of circulating CD56bright NK could be potential biomarkers in melanoma patients.
Methods
Melanoma patients. Blood was obtained from melanoma patients included in a phase I clinical trial 
(ClinicalTrials.gov; Identifier: NCT00112229) upon written informed consent. Eligibility criteria and study 
design has been previously described28. The study was designed, approved and conducted according to relevant 
regulatory standards approved by the Ethics Commission for Clinical Research of the Faculty of Medicine and 
University of Lausanne (Lausanne, Switzerland), Swissmedic (Swiss Agency for Therapeutic Product) and the 
Protocol Review Committee of the Ludwig Institute for Cancer Research (New York). The study was performed 
at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne. All 29 stage III/IV melanoma patients were 
included in the present study. Clinical details of all patients are assembled in Supplementary Table 1. Only sam-
ples from before the trial treatment were used in this study. Control PBMC from healthy donors where isolated 
from blood donations obtained from the Blood Transfusion center. The cells were isolated by density gradient 
centrifugation using Lymphoprep.
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Human cell preparation and flow cytometry. PBMCs were isolated from whole blood cells by 
Lymphoprep (Axis-Shield) centrifugation gradient and cryopreserved in liquid nitrogen. Frozen PBMCs were 
thawed in a water bath at 37 °C. They were stained immediately after thawing, first with antibodies directed 
against surface markers. The following antibodies were used for the NK cell phenotyping: anti-CD11a (BD 
Biosciences Cat# 347983, RRID:AB_400366), anti-PD-1 (BD Biosciences Cat# 557946, RRID:AB_647199), 
anti-CD56 (BioLegend Cat# 318322, RRID:AB_893389), anti-CD16 (Beckman Coulter Cat# A33098, RRID: 
AB_2728092), anti-NKp46 (BD Biosciences Cat#, RRID:AB_10894195), anti-NKG2D (BioLegend Cat# 320808, 
RRID:AB_492962), anti-CD8 (BioLegend Cat# 300920, RRID:AB_528885), anti-CD3 (Beckman Coulter 
Cat# A93687, RRID: AB_2728095), anti-CD127 (BioLegend Cat# 351310, RRID:AB_10960140), anti-CD14 
(Beckman Coulter Cat# B01175, RRID: AB_2728099), anti-CD19 (Beckman Coulter Cat# A96418, RRID: 
AB_2728101), anti-CD123 (BD Biosciences Cat# 563072, RRID: AB_2728102), anti-CD141 (BD Biosciences 
Cat# 563298, RRID: AB_2728103), anti-KLRG1 (A488, clone 13F12F2, provided by H. Pircher), anti-CD158b 
(Beckman Coulter Cat# IM2278U, RRID: AB_2728104), anti-NKG2A (Miltenyi Biotech Cat# 130-105-647, 
RRID:AB_2655388), anti-CD57 (BD Biosciences Cat# 333169, RRID: AB_2728105), anti-CD38 (Thermo Fisher 
Scientific Cat# 25-0389-42, RRID:AB_1724057), anti-CD95 (BioLegend Cat# 305612, RRID:AB_314550). 
Secondly, a live/dead staining (LIVE/DEAD™ Fixable Near-IR Dead Cell Thermo Fisher Scientific Cat# 
L-34975) was performed. Cells were fixed at room temperature (RT) for 30 minutes (1% formaldehyde buffer). 
Cells were washed and stained with anti–CTLA-4 (BD Biosciences Cat# 555855, RRID: AB_398615), in FACS 
buffer with 0.1% saponin for 30 minutes at RT. The following antibodies were used for the NK cell function-
ality panel: anti-CD56 (BioLegend Cat# 318328, RRID:AB_11218798), anti-CD16 (BioLegend Cat# 302026, 
RRID:AB_2278418), anti-CD3 (Thermo Fisher Scientific Cat# 47-0036-42, RRID:AB_10717514), anti-CD137 
(BioLegend Cat# 309826, RRID:AB_2566260), anti-CD69 (BioLegend Cat# 310926, RRID:AB_2074956), 
anti-NKp44 (BioLegend Cat# 325114, RRID:AB_2616752), anti-CD127 (BD Biosciences Cat# 563086, RRID: 
AB_2728655), anti-CD14 (Beckman Coulter Cat# B01175, RRID: AB_2728099), anti-CD19 (Beckman Coulter 
Cat# A96418, RRID: AB_2728101). Then a live/dead staining (LIVE/DEAD™ Fixable Aqua Dead Cell Stain 
Thermo Fisher Scientific Cat# L34965) was performed. Depending on the sample/panel, PBMCs were washed 
with Annexin V binding buffer (BD Biosciences) and stained for Annexin V (BD Biosciences Cat# 556419, RRID: 
AB_2665412). Cells were fixed at RT during 30 minutes (FoxP3 intracellular staining kit, eBioscience). Cells were 
washed and stained with; anti-TNFβ (Thermo Fisher Scientific Cat# BMS105FI, RRID:AB_10598519), anti-IFNγ 
(BioLegend Cat# 506804, RRID:AB_315454), anti-GMCSF (BioLegend Cat# 502310, RRID:AB_11150231), 
anti-IL-22 (R and D Systems Cat# IC7821P, RRID:AB_495011), anti-CCL4 (Thermo Fisher Scientific Cat# 
46-7540-42, RRID:AB_2573845), anti-IL-13 (BD Biosciences Cat# 561162, RRID:AB_10642586), anti-perforin 
(BioLegend Cat# 308104, RRID:AB_314702), anti-IL-4 (BioLegend Cat# 500810, RRID:AB_315129), 
anti-granzyme B (Thermo Fisher Scientific Cat# GRB17, RRID:AB_2536540), anti-TNFα (BioLegend Cat# 
502926, RRID:AB_2204081), anti-CCL3 (Miltenyi Biotech Cat# 130-103-631, RRID:AB_2651378) and anti-IL-5 
(BD Biosciences Cat# 554396, RRID:AB_398548) in FoxP3 intracellular staining kit permeabilisation buffer (eBi-
oscience) for 30 minutes at RT. CD4 regulatory T cells in patients PBMCs were identified ex vivo by staining 
with the following antibodies at the surface: anti-CD3 PerCP (BD Biosciences Cat# 345766, RRID:AB_2783791), 
anti-CD4 PE-Cy7 (Biosciences Cat# 348809, RRID: AB_2783789), anti-CD25 PE (BD Biosciences Cat# 341011, 
RRID: AB_2783790), anti-CD127 Pacific Blue (eBioscience Cat# 57-1278-73, AB_657602). Then a live/dead 
staining (LIVE/DEAD™ Fixable Aqua Dead Cell Stain Thermo Fisher Scientific Cat# L34965) was performed. 
The FoxP3 staining were performed after Fixation and Permeabilization using the FoxP3 intracellular stain-
ing kit permeabilisation buffer (eBioscience) using anti-FoxP3-FITC (eBioscience Cat# 11-5773-82, RRID: 
AB_11076963). Melan-A specific T cells were identified using tetramers as previously described28. In short: 
enriched CD8+ T cells were incubated with phycoerythrin-labeled HLA-A*0201/Melan-A/MART-1 A27L pep-
tide26-35 (ELAGIGILTV) tetramers (1 µg ml−1, 60 min, 4 °C) and then with antibodies (30 min, 4 °C).
Data were acquired on a Gallios (Beckman Coulter) and LSR-IITM Flow Cytometer (BD Bioscience) and ana-
lysed using FlowJo 10.4.2 (TreeStar).
In vitro stimulation. PBMCs were isolated from whole blood and cryopreserved in liquid nitrogen. Frozen 
PBMCs were thawed in a water bath at 37 °C. Cells were kept at 37 °C overnight in 20U/ml human recombi-
nant IL-2 (Proleukin) and RPMI (Gibco) with 10% FCS (Gibco). Cells were stimulated for 4 hours with 1 µg/ml 
Phorbol 12-Myristate 13-Acetate (PMA) (Sigma Aldrich) and 0.25 µg/ml Ionomycin, (Sigma Aldrich). 10 µg/ml 
of Brefeldin A (Sigma Aldrich) and 2 nM Monensin (Sigma Aldrich) were added to all conditions, as well as to the 
control conditions at the start of the stimulation.
statistics and analysis. Significance of single comparisons was assessed using the Mann–Whitney test, 
multiple comparisons were analysed using a two-way ANOVA or with a Kruskal-Wallis test, using the GraphPad 
Prism 8 software. Overall survival (OS) was defined as the time between enrolment in the phase I clinical trial 
and latest follow-up or death. Progression-free survival (PFS) was defined as the time between clinical trial enrol-
ment and relapse or progression of disease, based on whether the patient had no evidence of disease or evidence 
of disease at study entry, respectively. Apart from the clinical parameters, our data did not follow a normal dis-
tribution but a log distribution and was therefore log-transformed before statistical testing. The significance of 
Kaplan-Meier survival analysis was assessed by the Log-rank test (Prism 8). Cox proportional hazards model was 
used to test association with survival. Predictors were selected for multivariate regression based on results from 
univariate analyses, inclusion was based on statistical significance. Survival analysis was performed using the 
survival R package52.
9Scientific RepoRts |          (2019) 9:4487  | https://doi.org/10.1038/s41598-019-40933-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information Files).
References
 1. Chan, X. Y., Singh, A., Osman, N. & Piva, T. J. Role played by signalling pathways in overcoming BRAF inhibitor resistance in 
melanoma. Int. J. Mol. Sci. 18, 1–13 (2017).
 2. Wolchok, J. D. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 
NEJMoa1709684, https://doi.org/10.1056/NEJMoa1709684 (2017).
 3. Hsu, J. et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J. Clin. Invest. 128, 4654–4668 (2018).
 4. Vivier, E. et al. Innate Lymphoid Cells: 10 Years On. Cell 174, 1054–1066 (2018).
 5. Ames, E. & Murphy, W. J. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol. 
Immunother. 63, 21–28 (2014).
 6. Vivier, E. et al. Innate or Adaptive Immunity? The Example of Natural Killer Cells. Science 331, 44–49 (2011).
 7. Crome, S. Q., Lang, P. A., Lang, K. S. & Ohashi, P. S. Natural killer cells regulate diverse T cell responses. Trends Immunol. 34, 
342–349 (2013).
 8. Kim, S., Iizuka, K., Aguila, H. L., Weissman, I. L. & Yokoyama, W. M. In vivo natural killer cell activities revealed by natural killer 
cell-deficient mice. Proc. Natl. Acad. Sci. 97, 2731–2736 (2000).
 9. Iannello, A. & Raulet, D. H. Immune Surveillance of Unhealthy Cells by Natural Killer cells. Cold Spring Harb Symp Quant Biol. 78, 
249–257 (2013).
 10. Whiteside, T. L. & Herberman, R. B. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 7, 
704–710 (1995).
 11. Imai, K., Matsuyama, S., Miyake, S., Suga, K. & Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer 
incidence: an 11-year follow-up study of a general population. Lancet 356, 1795–1799 (2000).
 12. O’Sullivan, T. et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J. Exp. Med. 209, 
1869–1882 (2012).
 13. Ni, J., Miller, M., Stojanovic, A., Garbi, N. & Cerwenka, A. Sustained effector function of IL-12/15/18–preactivated NK cells against 
established tumors. J. Exp. Med. 209, 2351–2365 (2012).
 14. Levi, I. et al. Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6 (2015).
 15. Mirjacic Martinovic, K. M. et al. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-
1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients. Melanoma Res. 24, 295–304 
(2014).
 16. Fregni, G. et al. Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different 
Clinical Stages. PLoS One 8, 1–9 (2013).
 17. Ali, T. H. et al. Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma 
patients. Nat. Commun. 5, 1–9 (2014).
 18. Konjević, G., Miräjaić Martinovi, K., Jurišić, V., Babović, N. & Spužić, I. Biomarkers of suppressed natural killer (NK) cell function 
in metastatic melanoma: Decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers 14, 258–270 
(2009).
 19. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
 20. Coca, S. et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79, 
2320–2328 (1997).
 21. Villegas, F. R. et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung 
cancer. Lung Cancer 35, 23–28 (2002).
 22. Ishigami, S. et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88, 577–583 (2000).
 23. Messaoudene, M. et al. Mature cytotoxic CD56bright/CD16+ natural killer cells can infiltrate lymph nodes adjacent to metastatic 
melanoma. Cancer Res. 74, 81–92 (2014).
 24. Murray, S. & Lundqvist, A. Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being 
in the right place at the right time, with resilience. Hum. Vaccin. Immunother. 12, 607–611 (2016).
 25. Tallerico, R. et al. IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. 
Oncoimmunology 6 (2017).
 26. André, P. et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK 
Cells. Cell 1731–1743, https://doi.org/10.1016/j.cell.2018.10.014 (2018).
 27. Tietze, J. K., Angelova, D., Heppt, M. V., Ruzicka, T. & Berking, C. Low baseline levels of NK cells may predict a positive response to 
ipilimumab in melanoma therapy. Exp. Dermatol. 26, 622–629 (2017).
 28. Baumgaertner, P. et al. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int. J. Cancer 
130, 2607–2617 (2012).
 29. Malavasi, F. et al. CD38 and CD157 as Receptors of the Immune System: A Bridge Between Innate and Adaptive Immunity Fabio. 
Mol. Med. 13, 30–39 (2007).
 30. Ohta, A. & Sitkovsky, M. Extracellular adenosine-mediated modulation of regulatory T cells. Front. Immunol. 5, 1–9 (2014).
 31. Fauriat, C., Long, E. E. O., Ljunggren, H.-G. & Bryceson, Y. T. Regulation of human NK-cell cytokine and chemokine production by 
target cell recognition. Immunobiology 115, 2167–2176 (2010).
 32. Stabile, H., Fionda, C., Gismondi, A. & Santoni, A. Role of distinct natural killer cell subsets in anticancer response. Front. Immunol. 
8, 1–8 (2017).
 33. Amand, M. et al. Human CD56dimCD16dimCells As an Individualized Natural Killer Cell Subset. Front. Immunol. 8 (2017).
 34. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–74 (2011).
 35. Morandi, F. et al. CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells 
Inhibiting Autologous CD4+ T Cell Proliferation. J. Immunol. 195, 965–72 (2015).
 36. Waggoner, S. N., Cornberg, M., Selin, L. K. & Welsh, R. M. Natural killer cells act as rheostats modulating antiviral T cells. Nature 
481, 394–398 (2012).
 37. Waggoner, S. N., Daniels, K. A. & Welsh, R. M. Therapeutic Depletion of Natural Killer Cells Controls Persistent Infection. J. Virol. 
88, 1953–1960 (2014).
 38. Crouse, J., Kalinke, U. & Oxenius, A. Regulation of antiviral T cell responses by type i interferons. Nat. Rev. Immunol. 15, 231–242 
(2015).
 39. Fregni, G., Perier, A., Avril, M.-F. & Caignard, A. NK cells sense tumors, course of disease and treatments. Oncoimmunology 1, 38–47 
(2012).
 40. Shi, Y. et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: What we do and don’t know. Cell 
Res. 16, 126–133 (2006).
 41. Hodi, F. S. et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical 
trial. JAMA - J. Am. Med. Assoc. 312, 1744–1753 (2014).
1 0Scientific RepoRts |          (2019) 9:4487  | https://doi.org/10.1038/s41598-019-40933-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 42. Neubert, N. J. et al. Broad and conserved immune regulation by genetically heterogeneous melanoma cells. Cancer Res. 77, 
1623–1636 (2017).
 43. Deauvieau, F. et al. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. Int. J. 
Cancer 136, 1085–1094 (2015).
 44. Nakasone, Y. et al. Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 
melanoma. Am. J. Pathol. 180, 365–374 (2012).
 45. Fu, B. et al. Natural killer cells promote immune tolerance by regulating inflammatory TH17 cells at the human maternal-fetal 
interface. Proc. Natl. Acad. Sci. 110, E231–E240 (2013).
 46. Ashkar, A. A., Di Santo, J. P. & Croy, B. A. Interferon gamma contributes to initiation of uterine vascular modification, decidual 
integrity, and uterine natural killer cell maturation during normal murine pregnancy. J. Exp. Med. 192, 259–70 (2000).
 47. Vacca, P. et al. Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and 
immunosuppression. Proc. Natl. Acad. Sci. USA 107, 11918–23 (2010).
 48. Buyyounouski, M. K. et al. Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition 
Cancer Staging Manual. CA. Cancer J. Clin. 67, 245–253 (2017).
 49. Knackstedt, T., Knackstedt, R. W., Couto, R. & Gastman, B. Malignant melanoma:: Diagnostic and Management Update. Plast. 
Reconstr. Surg. 142, 701–711 (2018).
 50. Wang, F., Tian, Z. & Wei, H. Genomic expression profiling of NK cells in health and disease. Eur. J. Immunol. 45, 661–678 (2015).
 51. Michel, T. et al. Human CD56 bright NK Cells: An Update. J. Immunol. 196, 2923–2931 (2016).
 52. Themeau, T. A Package for Survival Analysis in S. Version 2.38 (2015).
Acknowledgements
We are obliged to thank the patients and healthy blood donors for their dedicated collaboration. The authors 
gratefully acknowledge Nicole Montandon for sample processing, and Pascale Anderle and Julien Racle for 
statistical advice. We also thank Karin de Visser, Werner Held and Paula Marcos Mondéjar for collaboration, 
support and expert advice, and Hanspeter Pircher for providing the KLRG1 antibody. This project was supported 
by SwissTransMed (KIP 18), Switzerland (to K.d.J.), the Cancer Research Institute, USA (to K.d.J., H.M.E.H.), the 
Swiss Cancer Research Foundation (to S.N.), Alfred and Annemarie von Sick, Switzerland (to H.M.E.H., H.O.S.) 
and the University of Lausanne, Switzerland (to A.E., P.B., D.E.S.).
Author Contributions
Conception and design: K.d.J., P.B. and D.E.S. Acquisition of data: K.d.J. and A.E. Analysis and interpretation 
of data: K.d.J., A.E., S.N., H.M.E.H., H.O.S., P.B. and D.E.S. Writing, review and revision of manuscript: K.d.J., 
A.E., S.N., H.M.E.H., H.O.S., P.B. and D.E.S. Technical and material support: S.N., H.M.E.H. and H.O.S. Study 
supervision: P.B. and D.E.S.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-40933-8.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
